Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

[1]  O. Nanni,et al.  Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy , 2016, Breast Cancer Research and Treatment.

[2]  M. Mete,et al.  Metformin Attenuates 131 I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer , 2016 .

[3]  M. Mete,et al.  Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer. , 2016, Thyroid.

[4]  Peter Kraft,et al.  Identification of Novel Genetic Markers of Breast Cancer Survival , 2015, Journal of the National Cancer Institute.

[5]  Bingshu E. Chen,et al.  Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. , 2015, Journal of the National Cancer Institute.

[6]  L. Ford,et al.  Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders , 2014, Cancer Prevention Research.

[7]  O. Nanni,et al.  Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[8]  E. Perez,et al.  Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer , 2012, Cancer.

[9]  G. Hortobagyi,et al.  Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. , 2012, Clinical breast cancer.

[10]  A. Luini,et al.  Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Edge,et al.  Impact of body mass index on clinical outcomes in triple‐negative breast cancer , 2011, Cancer.

[12]  R. Greil,et al.  Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Naoto T. Ueno,et al.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST , 2010, Journal of Cancer.

[14]  Funda Meric-Bernstam,et al.  Metformin: A Therapeutic Opportunity in Breast Cancer , 2010, Clinical Cancer Research.

[15]  M. Cazzaniga,et al.  Is it Time to Test Metformin in Breast Cancer Clinical Trials? , 2009, Cancer Epidemiology Biomarkers & Prevention.

[16]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[17]  M. Pollak,et al.  The Type 1 Insulin-Like Growth Factor Receptor Pathway , 2008, Clinical Cancer Research.

[18]  H. Howlett,et al.  Metformin therapy and clinical uses , 2008, Diabetes & vascular disease research.

[19]  M. Pollak.  Targeting insulin and insulin-like growth factor signalling in oncology. , 2008, Current opinion in pharmacology.

[20]  B. Zinman,et al.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy , 2008, Diabetologia.

[21]  A. Belfiore.  The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. , 2007, Current pharmaceutical design.

[22]  D. Yee,et al.  Disrupting insulin-like growth factor signaling as a potential cancer therapy , 2007, Molecular Cancer Therapeutics.

[23]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[24]  P. Richardson,et al.  Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. , 2006, Journal of Clinical Oncology.

[25]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[26]  D. Boyd,et al.  Insulin and Cancer , 2003, Integrative cancer therapies.

[27]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[28]  B. Hoffman,et al.  Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study , 2002 .

[29]  B. Hoffman,et al.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Kiechl,et al.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. , 1998, Diabetes.